| Why switch from warfarin to NOACs? | Intern Emerg Med | 2016 Apr | 26972708 |
| A Review of the Clinical Subgroup Analyses From the RE-LY Trial. | Rev Cardiovasc Med | 2016 | 27667379 |
| Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. | J Enzyme Inhib Med Chem | 2016 | 25683083 |
| Mediterranean diet reduces thromboxane A2 production in atrial fibrillationpatients. | Clin Nutr | 2015 Oct | 25288566 |
| Edoxaban: a review in nonvalvular atrial fibrillation. | Am J Cardiovasc Drugs | 2015 Oct | 26369340 |
| Cytochrome P450-mediated warfarin metabolic ability is not a critical determinantof warfarin sensitivity in avian species: In vitro assays in several birds and invivo assays in chicken. | Environ Toxicol Chem | 2015 Oct | 25959534 |
| Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal DialysisPatient. | Perit Dial Int | 2015 Nov | 26702005 |
| Trends and Characteristics of Emergency Department Patients Prescribed Novel OralAnticoagulants. | J Emerg Med | 2015 Nov | 26149803 |
| Pharmacogenomics and personalized medicine: a review focused on their applicationin the Chinese population. | Acta Pharmacol Sin | 2015 May | 25891088 |
| Novel oral anticoagulants: efficacy, laboratory measurement, and approaches toemergent reversal. | Arch Pathol Lab Med | 2015 May | 25927153 |